• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

达巴万星作为革兰阳性菌感染性心内膜炎的初始和序贯治疗：维也纳总医院 2 年经验。

Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna.

机构信息

Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Austria.

Institute for Infectious Diseases and Infection Control, Jena University Hospital.

出版信息

Clin Infect Dis. 2018 Aug 16;67(5):795-798. doi: 10.1093/cid/ciy279.

DOI:10.1093/cid/ciy279
PMID:29659732
Abstract

The clinical outcomes and safety of dalbavancin as primary and sequential treatment of gram-positive bacteremia with infective endocarditis were evaluated retrospectively. The clinical success rate was high (92.6%), but in 24 of 27 patients dalbavancin was used only after clearance of bacteria from the bloodstream.

摘要

回顾性评估了达巴万星作为革兰阳性菌菌血症合并感染性心内膜炎的一线和序贯治疗的临床疗效和安全性。临床成功率很高（92.6%），但在 27 例患者中，有 24 例仅在清除血流中的细菌后才使用达巴万星。

相似文献

1
Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna.达巴万星作为革兰阳性菌感染性心内膜炎的初始和序贯治疗：维也纳总医院 2 年经验。
Clin Infect Dis. 2018 Aug 16;67(5):795-798. doi: 10.1093/cid/ciy279.
2
Dalbavancin for infective endocarditis: a single centre experience.达巴万星治疗感染性心内膜炎：单中心经验。
J Chemother. 2021 Jul;33(4):256-262. doi: 10.1080/1120009X.2020.1823119. Epub 2020 Oct 19.
3
Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases.达巴万星作为静脉源革兰阳性菌血症患者的长期抑制疗法：一系列 4 例报告。
Infection. 2021 Feb;49(1):181-186. doi: 10.1007/s15010-020-01526-0. Epub 2020 Sep 23.
4
Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.真实世界中达巴万星治疗革兰阳性感染的多中心临床经验。
Int J Infect Dis. 2019 Apr;81:210-214. doi: 10.1016/j.ijid.2019.02.013. Epub 2019 Feb 19.
5
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.DALBACEN 队列研究：达巴万星治疗革兰阳性球菌引起的心内膜炎和/或血流感染患者的巩固治疗。
Ann Clin Microbiol Antimicrob. 2019 Oct 19;18(1):30. doi: 10.1186/s12941-019-0329-6.
6
Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.治疗革兰阳性皮肤和软组织感染、骨和关节感染的达巴万星真实世界经验。
Infection. 2019 Dec;47(6):1013-1020. doi: 10.1007/s15010-019-01354-x. Epub 2019 Sep 13.
7
Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review.达巴万星治疗革兰阳性菌感染性心内膜炎的序贯治疗：综述。
Int J Antimicrob Agents. 2023 Apr;61(4):106749. doi: 10.1016/j.ijantimicag.2023.106749. Epub 2023 Feb 8.
8
Treatment of Peptostreptococcus micros endocarditis with teicoplanin.用替考拉宁治疗微小消化链球菌心内膜炎
Clin Infect Dis. 1995 Aug;21(2):446-7. doi: 10.1093/clinids/21.2.446.
9
Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.比较达巴万星与标准护理在门诊治疗侵袭性革兰阳性感染中的疗效。
Int J Antimicrob Agents. 2020 Dec;56(6):106210. doi: 10.1016/j.ijantimicag.2020.106210. Epub 2020 Oct 23.
10
Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report.成功治疗 1 例药物敏感性金黄色葡萄球菌三尖瓣心内膜炎：1 例注射吸毒者门诊应用达巴万星治疗
Int J Infect Dis. 2020 Feb;91:202-205. doi: 10.1016/j.ijid.2019.12.008. Epub 2019 Dec 10.

引用本文的文献

1
A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?达巴万星和奥利万星用于革兰氏阳性菌感染的药理学比较综述：同类还是异类？
Infect Dis Ther. 2025 Sep 3. doi: 10.1007/s40121-025-01215-1.
2
Real-World Use of Dalbavancin in a United States Tertiary Referral Center.达巴万星在美国三级转诊中心的实际应用
Cureus. 2025 Mar 31;17(3):e81505. doi: 10.7759/cureus.81505. eCollection 2025 Mar.
3
Common Bacterial Infections in Persons Who Inject Drugs.注射吸毒者中的常见细菌感染
Medicines (Basel). 2025 Mar 28;12(2):8. doi: 10.3390/medicines12020008.
4
Trends in the Management of Infective Endocarditis for Patients Who Inject Drugs: A Survey of Healthcare Facilities in Tennessee.注射毒品患者感染性心内膜炎的管理趋势：田纳西州医疗机构调查
Open Forum Infect Dis. 2025 Apr 3;12(4):ofaf150. doi: 10.1093/ofid/ofaf150. eCollection 2025 Apr.
5
Treatment of Complicated Gram-Positive Bacteremia and Infective Endocarditis.复杂性革兰氏阳性菌血症和感染性心内膜炎的治疗
Drugs. 2025 Feb;85(2):193-214. doi: 10.1007/s40265-024-02135-z. Epub 2024 Dec 25.
6
A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis.达巴万星作为感染性心内膜炎序贯治疗药物疗效的系统评价。
Infection. 2025 Feb;53(1):15-23. doi: 10.1007/s15010-024-02393-9. Epub 2024 Sep 26.
7
Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network.达巴万星与传染病网络中标准治疗方案对比的临床、组织及药物经济学视角
Glob Reg Health Technol Assess. 2024 Jul 29;11(Suppl 2):5-12. doi: 10.33393/grhta.2024.3094. eCollection 2024 Jan-Dec.
8
Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overview.达巴万星在抗菌药物耐药时代治疗革兰氏阳性菌感染中的应用概述
Glob Reg Health Technol Assess. 2024 Jul 29;11(Suppl 2):1-4. doi: 10.33393/grhta.2024.3108. eCollection 2024 Jan-Dec.
9
Simulated Target Attainment of Multidose Regimens of Dalbavancin for Prolonged Durations of Therapy.达巴万星多剂量方案在延长治疗疗程中的模拟目标达成情况。
Open Forum Infect Dis. 2024 Jun 6;11(6):ofae315. doi: 10.1093/ofid/ofae315. eCollection 2024 Jun.
10
Dalbavancin as consolidation therapy for infective endocarditis in patients with comorbidity. A real world experience.达巴万星治疗合并症患者感染性心内膜炎的巩固治疗：真实世界经验。
Rev Esp Quimioter. 2024 Aug;37(4):334-340. doi: 10.37201/req/012.2024. Epub 2024 Jun 17.